Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern NashanKlinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, GermanyAbstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical tria...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e03be2da5bdf40568c482564d4475e36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e03be2da5bdf40568c482564d4475e36
record_format	dspace
spelling	oai:doaj.org-article:e03be2da5bdf40568c482564d4475e362021-12-02T00:47:38ZBasiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?1177-54751177-5491https://doaj.org/article/e03be2da5bdf40568c482564d4475e362009-01-01T00:00:00Zhttp://www.dovepress.com/basiliximab-induction-therapy-in-kidney-transplantation-benefits-for-l-a2781https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern NashanKlinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, GermanyAbstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.Keywords: basiliximab, induction therapy, long term graft survival, renal transplantation Martina KochThomas BeckerRainer LueckMichael NeippJuergen KlempnauerBjoern NashanDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 51-56 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Martina Koch Thomas Becker Rainer Lueck Michael Neipp Juergen Klempnauer Bjoern Nashan Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
description	Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern NashanKlinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, GermanyAbstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.Keywords: basiliximab, induction therapy, long term graft survival, renal transplantation
format	article
author	Martina Koch Thomas Becker Rainer Lueck Michael Neipp Juergen Klempnauer Bjoern Nashan
author_facet	Martina Koch Thomas Becker Rainer Lueck Michael Neipp Juergen Klempnauer Bjoern Nashan
author_sort	Martina Koch
title	Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
title_short	Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
title_full	Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
title_fullStr	Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
title_full_unstemmed	Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
title_sort	basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years?
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/e03be2da5bdf40568c482564d4475e36
work_keys_str_mv	AT martinakoch basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years AT thomasbecker basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years AT rainerlueck basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years AT michaelneipp basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years AT juergenklempnauer basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years AT bjoernnashan basiliximabinductiontherapyinkidneytransplantationbenefitsforlongtermallograftfunctionafter10years
_version_	1718403529902653440

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Ejemplares similares